MDLN Medline Inc.

Astellas Pharma CEO Naoki Okamura and 2375 Waterview Drive (Astellas, Transwestern)Astellas Pharmaceutical is testing the waters of the suburban Chicago office market by putting its office complex in Northbrook up for sale. Japan-based Astellas’s office property spans two buildings at 2375 Waterview Drive and is being billed as a potential sale-leaseback opportunity. The company occupies 84,887 square feet in the south building on the property, according to Crain’s. The total two-building proper

Medline (MDLN) is drawing investor attention after a recent share price pullback, with the stock down about 7% over the past month and roughly 9% over the past 3 months. Over a longer stretch, the share price return tells a similar story, with Medline down about 22% year to date. This indicates that momentum has been fading as investors reassess both the company’s growth outlook and the risks they are willing to price into the stock. Compare Medline's recent pullback with a curated 35 high...

Medline shares have fallen sharply this year, which puts the spotlight squarely on whether the current US$31.64 price is still aligned with the cash the business is expected to generate. With a Discounted Cash Flow (DCF) intrinsic value estimate available, the central question is how that cash flow outlook lines up with the market’s reset expectations. The stock is down 22.1% year to date, so the market has already repriced Medline and raised fresh questions about what its future cash...

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” second-quarter 2026 investor letter. The letter can be downloaded here. During the quarter, the Fund (Investor Shares) returned 17.49% (net of fees), outperforming the Russell 1000 Growth Index’s 16.74%. Holdings in Information Technology and Consumer Discretionary sectors boosted relative returns, while Communication Services […]

During the September 8 episode of Mad Money, Jim Cramer compared Medline Inc. (NASDAQ:MDLN) to Arizona Cardinals rookie running back Jeremiyah Love and highlighted how temporary setbacks create a unique entry window for patient investors. He remarked: For my third running back, let’s bring in some new blood, please. I’m bringing in Medline, the largest […]

Artisan Partners, an investment management company, released its second-quarter 2026 investor commentary for the “Artisan Global Opportunities Strategy”. The letter can be downloaded here. Global equities rebounded sharply during the quarter, with the MSCI ACWI Index returning 15.3% as resilient economic growth, strong corporate earnings, and continued enthusiasm around artificial intelligence supported markets despite persistent inflation, […]

Sales hit $7.7 billion with 11.6% growth, but EBITDA guidance fell on cost pressures.

Medline Inc (MDLN) raises organic sales guidance to 9%-10% while navigating inflationary pressures and operational investments to support record customer demand.

Medline (NASDAQ:MDLN) reported second-quarter 2026 net sales growth of 12% to $7.7 billion, supported by demand across its medical-surgical product and supply-chain businesses, while raising its full-year organic sales outlook. The company also lowered its adjusted EBITDA guidance, citing operationa

Insulet stock crashed Wednesday after lowering sales guidance for its body-worn insulin pump, Omnipod, in the back half of the year.

Although the revenue and EPS for Medline (MDLN) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Investing.com -- Medline shares slumped more than 13% in premarket trading Wednesday after the medical supply distributor reported a 58.3% year-over-year drop in second-quarter net income, weighed down by losses tied to a fire that destroyed one of its distribution centers.

Ranpak (NYSE:PACK) reported second-quarter revenue growth driven by a sharp increase in automation equipment sales, while management said it remains on track to meet its full-year outlook and generate roughly $60 million in automation revenue in 2026. Chairman and CEO Omar Asali said automation rev

COO retirement and new client agreement put Medline (MDLN) in focus Medline (MDLN) is drawing investor attention after Chief Operating Officer Stephen L. Miller announced plans to retire for health-related reasons, and the company also signed a new Prime Vendor agreement with Allina Health. See our latest analysis for Medline. Recent news around the COO transition, the Allina Health agreement and new distribution capacity in California comes as Medline’s 30 day share price return is 8.76%,...